Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Study results from L. Aurisicchio and colleagues broaden understanding of cancer vaccines
April 22nd, 2009
"Puepose: Oligodeoxynucleotides containing unmethylated CpG dinucleoticles induce innate and adaptive immunity through Toll-like receptor 9 (TLR9). In the present study, we have examined the ability of a novel agonist of TLR9, called immunomodulatory oligonucleoticle (IMO), to enhance effects of a HER-2/neu plasmid DNA electroporation/adenovirus (DNA-EP/Ad) vaccine," researchers in Pomezia, Italy report. "BALB/NeuT mice were treated with DNA-EP vaccine alone, IMO alone, or the combination of two agents starting at week 13, when all mice showed mammary neoplasia. Tumor growth and survival were documented. Antibody and CD8(+) T-cell responses were determined. Peptide...
Source: Vaccine Weekly (2009-04-22)
|
